Consequently, loss of FPGS activity is a well-established mechanism of resistance to MTX and other polyglutamylation-dependent antifolates in leukemic cell lines as well as in childhood ALL patients.
FPGS splicing in MTX resistance of childhood ALL 9 & in the splicing analysis of additional genes are listed in Supplemental Table S2 . PCR was performed using 2x ReddyMix PCR master mix according to the manufacturer's instructions (Thermo Fisher Scientific, Waltham, MA, USA). Subsequently, the obtained PCR products were resolved on 2% agarose gels containing ethidium bromide. The identity of all obtained FPGS fragments that had a different size from the expected (wild type FPGS) PCR product was confirmed by DNA sequencing.
DNa sequencing
PCR products were resolved on 2% agarose gels, followed by the excision of selected bands. DNA fragments were purified using the GeneJET gel extraction kit (Thermo Fisher Scientific) according to manufacturers' instructions. DNA sequencing was performed using BigDye Terminator Cycle Sequencing Kit and the Genetic Analyzer 3500 System from ABI (Applied Biosystems, Foster City, CA, USA) using the same primers as described above for standard PCR reactions (Supplemental Table S1 ).
Quantification with real-time pcr
Real-time PCR was performed using the Light Cycler 480 II System (Roche). Diagnostic primers (Supplemental Table S3 .) detecting specific wild type or altered junctions between selected exons of FPGS were used together with the Light Cycler 480 SYBR Green I Master mix (Roche) according to the manufacturers' protocol. The data were expressed as relative to the expression of the housekeeping gene β-glucuronidase (GusB).
Flow cytometric analysis
For the apoptosis assay, cells were stained with 7AAD and FITC-conjugated anti-Annexin V antibody (both from Becton Dickinson, Mountain View, CA, USA), followed by fluorescence measurement using FACScalibur (Becton Dickinson). Analysis was performed using Cell Quest Pro software (Becton Dickinson).
Splice site analysis
The Human Splicing Finder (HSF) algorithm (http://www.umd.be/HSF/) was used to analyze the retained fragment of intron 8 for potential alternative splice site signals. 29 
3D protein modeling
FPGS sequences containing selected splicing alterations were created based on mRNA sequence from Genebank (NM_004957.4). Then, a 3D model of the human FPGS was generated as previously described 17 using the L. casei FPGS crystal structure which was crystallized in complex with TMF (5,10-methylene-6-hydrofolic acid) and ACQ (ATP analogue). 30 
FpGS activity assay and Western blot analysis
Generation of pIRES2-EGFP (Clontech, Palo Alto, CA, USA) carrying the WT hFPGS was described previously. 25 Exon deletions were introduced into pIRES2-EGFP/hFPGS using site-directed mutagenesis as described previously. 25 The catalytic activity of FPGS was determined as detailed elsewhere. 16, 31 To introduce intron retentions, synthetic sequences of introns (Genscript, Piscataway, 1 2 3 4 5 6 7 8
FPGS splicing in MTX resistance of childhood ALL 9 & NJ, USA) were cloned into pIRES2-EGFP/hFPGS using SacI (New England Biolabs, Ipswitch, MA, USA) and BglII (New England Biolabs) as restriction enzymes. In short, 10 6 HeLa cells were seeded in 10 cm plates and transfected with the indicated constructs using Linear Polyethylenimine (PEI, MW 25,000) transfection reagent (Polysciences, Pennsylvania, USA) at a ratio of 3 μg PEI : 1 μg DNA. Twenty four h after transfection, cells were scraped off the plates using a rubber policeman and suspended in 150 μl of extraction buffer (50 mM Tris-HCl, 20 mM KCl, 10 mM MgCl 2 and 5 mM dithiotreitol, at pH 7.5) and frozen. Crude cell extracts were prepared by sonication (Misonix Microson, amplitude 2, 3 x 5 s with 20 s intervals, on ice) followed by centrifugation (20, 
Mtt cytotoxicity assay
Cytotoxicity of doxorubicin and dexamethasone in CCRF-CEM and CEM/R30dm cells was undertaken after a continuous 72 h exposure using the colorimetric MTT reduction assay as described previously. 32 The results are expressed as IC 50 values -drug concentration that inhibits cell growth by 50%.
RESULTS

FpGS splicing alterations are abundant in blasts of aLL patients
We first assessed the spectrum of FPGS splicing alterations in adult and childhood ALL patient specimens. Using a comprehensive assay we first screened 12 childhood and 14 adult ALL BM and PB specimens. In this initial screen, aimed at detection of the presence of any FPGS splice variants, we used a PCR-based assay spanning the entire FPGS mRNA sequence (primer pairs used generated overlapping amplicons), while covering all the exon-exon junctions. It should be emphasized that the expected band (wild type; WT) of each PCR product only reveals the usage of canonical splice sites in these particular regions, which does not imply that the whole gene is properly spliced. Subsequently, the identity of the most dominant products was confirmed by DNA sequencing. This screen revealed a wide spectrum of splicing alterations including skipping of exons 2, 5, 6, 10 and 12 as well as retention of intron 6 and a 86 base-pair fragment of intron 8 ( Figure 1A and 1B). Interestingly, retention of intron 6 and partial retention (PR) of intron 8 were detected either individually or together in a single FPGS fragment. The majority of alterations were detected by multiple primer pairs, verifying that they do not constitute PCR artifacts. The abundance and frequency of the detected alterations clearly varied among the analyzed samples ( and 1B). Due to limited material which was available for ALL patients, we only quantified the most frequent FPGS splicing alteration -intron 8 PR in this initial ALL patient cohort. The ratio of intron 8 PR relative to the WT PCR product of this FPGS fragment (8PR/8WT) quantified using real-time PCR was overall representative of the tendencies seen in the semi-quantitative PCR used for the initial screen (see Figure 1 and Supplemental Figure S1 ), although some ratios were underrepresented on gels. The ratio of FPGS 8PR/8WT varied between 6.6% and as high as 37.4% in pediatric ALL samples and between 5.3 and 36.7% in adult ALL, indicating a large interpersonal variation in expression of this splice variant. Moreover, each ALL patient included in the screen displayed multiple FPGS splicing alterations (Table 2) , which might co-exist in a single transcript or affect different transcripts. Since, as mentioned before the PCR assay used to screen consecutive fragments of FPGS mRNA, a transcript which appears as WT in one FPGS region, might contain a splicing alteration in another region. 
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Non-malignant adult PB (N) We next investigated whether or not FPGS splicing alterations are specific for leukemic cells or can also be found in non-malignant cells. Towards this end, 9 PB and 2 BM specimens from healthy adults were analyzed along with 6 samples from cardiac patients ( Figure 1C-E) ; the latter included 3 BM and 1 PB samples from children and 2 BM specimens from adults. In accordance with the presence of PR of intron 8 in 100% of the leukemia samples, it was also found in all non-malignant BM and PB samples. Strikingly, the majority of FPGS splicing alterations which we identified herein in leukemic samples, were also found in the non-malignant BM cells, regardless of whether they were derived from healthy donors or cardiac patients. In contrast, all PB samples of healthy individuals were free of FPGS splicing alterations with the exception of intron 8 PR ( Figure 1E ) and exon 10 skipping (Table 1) , both of which were detected at low levels. It appears that fewer alterations occurred in PB than in BM cells of both leukemic and normal cell origin ( Figure 1 and Table 1 ). Moreover, no differences in FPGS splicing were detected upon separate examination of several subtypes of BM cells (including CD34+ progenitors, B-and T-lymphocytes, as well as monocytes, data not shown). Five splicing alterations (exon skipping -Δexon5, Δexon10, Δexon12, and intron retentions -::intron 6 and ::intron 6 + PR of intron 8) introduced a frame-shift and a premature translation termination codon (PTC) into the FPGS mRNA, whereas the PR of intron 8 introduced only a PTC (Table 3 ). All these alterations resulted in drastic truncations of FPGS, depriving it of its C-terminal L-glutamate binding site, which is essential for the polyglutamylation reaction. 30, 33 Intriguingly, deletions introduced by exon 2 and exon 6 skipping resulted in neither a frame-shift nor in the introduction of a PTC. Therefore, we assessed the possible deleterious consequences of these FPGS splice alterations on the structure and function of FPGS. Computational 3D models were generated ( Figure 2A ) based on the structure of L. casei FPGS, which was crystallized with ACQ (an ATP analogue) and TMF (5,10-methylene-6-hydrofolic acid). 30 Analysis of exon 2 and exon 6 skipping using this computational model ( Figure 2B and 2C) revealed that both alterations introduced deletions which were located at the N-terminus of FPGS and did not directly affect any of the most important functional domains of FPGS (p-loop, Ω-loop, and glutamate binding site). However, they occurred in a relatively close proximity to these active site elements, in particular to the Ω-loop. Exon 6 skipping resulted in deletion of an α-helix located in a close proximity to the folate binding site. Similarly, exon 2 skipping deprived FPGS protein of the first 2 α-helices, which are adjacent to, and therefore likely to stabilize other structural elements engaged directly in folate substrate binding. Therefore, it is likely that structural alterations resulting from exon 2 and exon 6 skipping adversely affect the 3D conformation of FPGS and consequently alter the folate binding capacity.
To corroborate these structural predictions, we evaluated the impact of splicing alterations on the catalytic activity of FPGS. HeLa cells were transiently transfected with constructs harboring the wild type FPGS form or selected splice alterations followed by FPGS activity assay by directly determining MTX polyglutamylation ( Figure 2D) . Overexpression of the WT FPGS resulted in high polyglutamylation activity ( Figure 2D , set as 100%) as compared to mock transfected cells (4.89%, SD=1.7). The activity assay revealed that all of the FPGS species containing splicing alterations displayed only 3.24 -27.44% compared to FPGS activity obtained in the WT FPGS transfection.
Short-term exposure to chemotherapeutic agents induces FpGS splicing alterations
To gain insight into the relationship between FPGS splicing alterations and MTX resistance, we investigated the dynamics of FPGS splicing alterations in response to MTX treatment. In this analysis, we studied the MTX-resistant human leukemia subline CCRF-CEM/R30dm which displayed a near complete loss of FPGS activity (~1% residual activity) while retaining normal mRNA levels. 18 This mode of MTX selection resulted in polyglutamylation-dependent MTX resistance in comparison to parental CCRF-CEM cells, as illustrated by cell growth inhibition assay using short-term exposures to MTX. 18, 27, 28 A single nucleotide shift (G1144A) was previously identified in CEM/R30dm which had no effect on FPGS activity. 23 In addition, CEM/R30dm cells exhibited most of the splicing alterations identified in ALL patient samples, of which intron 8 PR was particularly abundant (Table 3) , making it a good model to study drug-induced FPGS splicing alterations. Parental CCRF-CEM and CEM/R30dm cells were exposed to a range of clinically relevant MTX concentrations (100 -1000 nM) for 24 h, followed by RT-PCR analysis of FPGS splicing and flow cytometry-based apoptosis assay. The results show that in CEM/R30dm, but not in parental cells, the levels of the fragment corresponding to PR of intron 8 were gradually augmented upon exposure to increasing concentrations of MTX, as indicated by RT-PCR as well as real-time PCR ( Figure 3A and Supplemental Figure S2A ). The observed shift in FPGS splicing does not appear to be a direct result of stress-induced apoptosis, as the viability of CEM/R30dm cells was even slightly higher than that of parental CCRF-CEM cells (Supplemental Figure S3) . This finding suggests that altered FPGS splicing is associated with loss of polyglutamylation and consequent antifolate resistance in CEM/R30dm cells.
Prompted by these novel findings, we further investigated whether or not other polyglutamylation-dependent and polyglutamylation-independent antifolates can induce similar alterations in FPGS splicing. Parental CCRF-CEM and CEM/R30dm cells were exposed to a panel of antifolates (Supplemental Table S4 ), differing in their cellular target enzymes (dihydrofolate reductase or thymidylate synthase) and in their mode of entry into cells; hydrophilic antifolates entering cells via the reduced folate carrier and proton-coupled folate transporter, versus lipophilic antifolates which enter cells by diffusion. Surprisingly, all antifolates tested increased the level of PR of intron 8, regardless of their polyglutamylation dependence or their distinct properties regarding their cellular target enzyme and mode of entry into cells ( Figure 3B ).
Since the chemotherapeutic regimen of pediatric ALL patients also contains non-antifolate drugs, parental CCRF-CEM and CEM/R30dm cells were exposed to several non-antifolate chemotherapeutics; these included cytarabine (AraC) -a deoxycytidine analogue, doxorubicin (DXR) -a topoisomerase II Figure S2B and S2C) and apoptosis assay (Supplemental Figure S3) . The relative levels of intron 8 PR to the wild type exon 8 increased upon treatment with AraC. Strikingly, DXR was able to shift FPGS splicing in both leukemia cell lines at 600 nM towards intron 8 PR. In contrast, VCR and Dex had no effect on FPGS splicing. These findings point to a selective impact of certain chemotherapeutics on enhancement of impaired FPGS splicing. Viability of cells determined by the apoptosis assay showed similar decrease in parental CCRF-CEM and CEM/R30dm cells upon 24 h exposure with any of the drugs used, indicating that the observed alterations in FPGS splicing cannot be explained by events associated with apoptosis. Moreover, we analyzed drug induced splicing modulation in a selected panel of genes involved in apoptosis regulation (MCL1, FAS and Caspase-2) 34 and drug resistance (PSIP1 -gene implicated in cytarabine resistance in AML). 35 Different splicing patterns for MCL1 and FAS were observed between unexposed parental CCRF-CEM and CEM/R30dm cells (Supplemental Figure S4A ). Supporting our observations for FPGS splice alterations, MTX, AraC and DXR were also able to modulate splicing of the analyzed genes, although this was not obvious for VCR and Dex (Supplemental Figure S4B ). Some changes in splicing were also induced in parental CCRF-CEM cells, however, they were more pronounced in CEM/R30dm. Interestingly, a previous study showed that CEM/R30dm cells displayed a certain level of resistance to AraC but not to VCR (3.9-fold and 0.7-fold, respectively upon an intermittent drug exposure), when compared to the parental cells. 36 Hence, we also determined here the sensitivity of both CCRF-CEM cell lines to DXR (Supplemental Figure S5) . In support of our hypothesis, CEM/R30dm cells displayed 2.8-fold higher resistance to DXR, compared to parental CCRF-CEM cells.
dISCUSSION
In the current study we show that alterations in FPGS splicing are common events in ALL. The comprehensive RT-PCR-based screen performed on ALL patient specimens, and on MTXresistant CEM/R30dm cells revealed a spectrum of FPGS splicing alterations, further extending our earlier findings. 25 Most importantly, this is the first study demonstrating FPGS splicing alterations in pediatric ALL. Different isoforms of FPGS resulting from differential translation initiation have long been known to exist in leukemic cell lines. 37 Furthermore, human leukemic and hematopoietic cells have been reported to express 4 splice variants of FPGS based on alternative splicing of exon 1.
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Together with these early reports, our current findings constitute an extensive database of the assortment of FPGS splicing alterations occurring in ALL. We show that the abundance and variation of FPGS splicing alterations is much broader than initially anticipated and possibly includes various combinations of different alterations in a single transcript. This unexpectedly high level of complexity poses difficulties in determining the relative contribution of the individual alterations to the extent of decrease in FPGS activity. However, transcripts harboring splicing alterations will certainly result in loss of FPGS activity. Especially, if the multiplicity of detected splicing alterations affects distinct FPGS transcripts, they would altogether result in a substantial decrease in FPGS activity. Moreover, the majority of FPGS splicing alterations could also be detected in the BM of healthy individuals, indicating that they are not leukemia-specific but might be a common mechanism regulating FPGS activity. These observations, however, do not diminish the contribution of FPGS splicing alterations to the development of MTX resistance. Moreover, one may further suggest that certain splice variants Figure 1 ) and the same FPGS splicing profiles were shared by different subpopulations of BM cells. These observations suggest that elements of the BM microenvironment influence the regulation of FPGS splicing. However, the number of non-malignant BM control specimens and PB samples of both leukemic and normal origin analyzed in the current study is rather limited and needs to be expanded to larger patient cohorts. In addition, to characterize the impact of FPGS splicing alterations on MTX resistance in primary ALL one will also have to conduct a considerably larger study. Unlike point mutations, splicing alterations result in deletions or insertions of relatively large fragments. The actual fate of the altered FPGS transcripts has not been determined thus far; however, if translated, altered FPGS species are predicted to result in crippled proteins, which are devoid of catalytic activity. Consistently, our FPGS activity assay established that all of the splicing alterations studied here resulted in loss of FPGS function.
Additional evidence supporting the role of altered FPGS splicing in MTX resistance stems from our in vitro leukemia cell line experiments. We found that short-term exposure to MTX was sufficient to provoke an increase in the level of intron 8 PR, in MTX-resistant, FPGS-deficient CEM/R30dm cells, a phenomenon that did not occur in parental cells. Interestingly, exposure of CEM/R30dm cells to a spectrum of other antifolates also resulted in alterations in FPGS splicing, suggesting that this phenomenon is induced due to the suppression of the activity of key folate-dependent enzymes, which are the cellular targets of these antifolates including DHFR and TS. To determine whether or not alterations in FPGS splicing were also affected by drugs other than antifolates, we exposed leukemia cells to several chemotherapeutics commonly used in the treatment of ALL. Strikingly, treatment with AraC and DXR also induced PR of FPGS intron 8 in CEM/R30dm, in contrast to Dex and VCR, which had no effect on splicing. Interestingly, both DXR and AraC act at the DNA level, interfering with DNA replication. DXR intercalates into DNA and affects cellular transcriptome by stabilizing topoisomerase II as well as inducing histone eviction. 40, 41 AraC interferes with DNA polymerase upon incorporation into DNA. 42 Since splicing is influenced by transcription machinery and chromatin structure, it is possible that perturbations in these processes lead to altered splicing profiles thereby provoking drug resistance. DXR was previously shown to induce the retention of a 108bp intronic fragment of MDM2, a negative regulator of p53. This partial intron retention resulted in the introduction of a premature termination codon thereby resulting in the expression of a truncated MDM2 protein, which consequently leads to p53 accumulation. The authors suggested that this is a physiological response aimed to increase p53 expression under genotoxic stress. 43 Here we showed that PR of FPGS intron 8 is a naturally occurring variation which is further induced under cytotoxic stress including antifolates, DXR and AraC. In contrast, VCR binds to β-tubulin causing microtubule depolymerization and inhibition of mitosis, whereas Dex induces cell death via apoptotic and non-apoptotic pathways 44, 45 , in a mechanism that is still poorly understood, although known to involve the glucocorticoid receptor. We therefore hypothesize that drug induced down-regulation of FPGS and subsequent reduction in the intracellular pool of purine and pyrimidine nucleotides, which should eventually lead to cell-cycle arrest, acts as a defense mechanism against DNA replication-dependent drugs. We have recently shown that a similar mechanism of resistance to cell cycle dependent drugs (including antifolates) occurs in a range of solid tumors under hypoxic conditions. 46 Therefore, we speculate that among the protective responses to DNA replication-dependent drugs (i.e. DXR, AraC and antifolates), the induction of intron 8 PR of FPGS mRNA is clearly present. This hypothesis is further supported by the decreased sensitivity of CEM/ R30dm cells to AraC and DXR but not to VCR. 36 On the other hand, CEM/R30dm cells were highly resistant to Dex (data not shown), which was not associated with alterations in FPGS splicing. Thus, it is possible that splicing of genes involved in Dex resistance is also altered in this leukemia cell line. In fact, a pilot analysis performed on a small set of genes involved in apoptosis regulation and drug resistance revealed that similar splicing alterations were induced by MTX, AraC and DXR in CEM/R30dm cells. These moderate changes shifted splicing of MCL1 and CASP2 towards their anti-apoptotic isoforms, potentially increasing apoptosis-resistance of this cell line. In contrast, VCR and Dex did not affect splicing patterns of the analyzed genes, supporting the hypothesis that splicing alterations observed in CEM/R30dm in this study constitute a mechanism of resistance to DNA replication dependent drugs. These findings point to a more general splicing defect involving multiple genes thereby resulting in multidrug resistance to a broader spectrum of cancer chemotherapeutics. A growing body of evidence points to aberrant splicing as an emerging mechanism of anticancer drug resistance. 47 In support of this notion, alterations in splicing of deoxycytidine kinase (dCK), an enzyme crucial for the cytotoxic activity of AraC, were shown to be associated with AraC resistance. 48 Moreover, several studies link altered splicing with induction of multidrug resistance via deregulation of splicing factors involved in the regulation of apoptosis, including the FAS receptor 49 and Bcl-X. 50 We have previously shown that resistance of THP1 (AML) and U937 cells to capecitabine (a precursor of 5-fluorouracil) is associated with decreased activity of TP (thymidine phosphorylase), resulting in a block of conversion of 5'-deoxyfluorouridine to 5-FU. We found that this capecitabine resistance was due to unsplicing of the TP pre-mRNA, caused by nuclear localization of hnRNPH1/ H2, which was not detectable in WT cells.
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Overall, our findings point to the fact that increased levels of splicing alterations in FPGS may result in decreased FPGS activity, thereby resulting in MTX resistance. Importantly, we further discovered here that FPGS splicing alterations were induced by antifolates and other unrelated chemotherapeutics, thereby presumably reflecting broad splicing alterations affecting multiple genes and assuring enhanced cell survival. This well based hypothesis warrants further studies particularly those evaluating the clinical relevance in large patient cohorts. Deciphering the molecular mechanisms underlying this phenomenon may open novel avenues for the development of reliable prognostic tools as well as efficacious therapeutic interventions in general, ALL in particular. In this respect, our findings with drug-provoked impaired FPGS splicing have important implications for the overcoming of this modality of drug resistance. Hence, detection of elevated levels of adverse splice variants in ALL patient samples could guide clinical decisions in the treatment of patients with chemotherapeutics which do not induce impaired splicing. Moreover, mutated and/or upregulated splicing factors, which likely constitute the basis of drug induced impaired FPGS splicing, could be targeted with selective small molecule inhibitors. Lastly, spliceosome inhibitors deserve further exploration for altering aberrant splicing profiles and re-sensitizing drug resistant cells. Ratio of 8PR/8WT (%) Ratio of 8P Table S1 . Primers used in the RT-PCR based screen of the whole FPGS mRNA for splicing alterations. 
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